GlaxoSmithKline plc and Royal Dutch Shell plc: 2 income champions to protect you from Brexit risks

GlaxoSmithKline plc (LON: GSK) and Royal Dutch Shell Plc (LON: RDSB) are two companies that could be immune to Brexit risks.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s one concern dominating the minds of investors at the moment and that’s Brexit. Indeed, if Britain votes to leave the EU on 23 June, the country will be subject to a multi-year period of uncertainty, and it’s this uncertainty that will cause investors the most pain.

To protect against uncertainty and any adverse effects that may come as a result of Britain’s decision to leave the EU, investors could look to large international firms with well-covered dividend yields and well-positioned to succeed in any economic environment.

Defensive business 

GlaxoSmithKline (LSE: GSK) is one such company. The pharmaceuticals giant is a world leader in the production of consumer pharmaceutical products, such as over-the-counter medicines, toothpaste and painkillers. What’s more, the group has a large vaccines division as well as a stake in ViiV Healthcare, a joint venture dedicated to delivering advances in treatment and care for people living with HIV. It’s extremely unlikely that any one of these businesses will see a sudden drop-off in demand for their products in the event of a Brexit.

Moreover, this year Glaxo is on track to report its first year of earnings growth since 2011, so there’s already a significant amount of positive sentiment surrounding the group. City analysts expect the company to report earnings growth of 16% this year, followed by growth of 5% for 2017.

Management has already come out to confirm it’s on track to meet this target. In fact, the first quarter of 2016 was one of the most impressive in several years for the company. Sales increased by 11%, to £6.2bn and earnings per share, excluding exceptional items and adjusted for currency, rose 8% to 19.8p. Shares in Glaxo currently trade at a forward P/E of 15.9 and support a dividend yield of 5.7%.

Global oil company 

Royal Dutch Shell (LSE: RDSB) is another large international company that’s unlikely to be significantly affected by a leave vote. As one of the largest oil traders in Europe and one of the biggest integrated oil companies in the world, Shell is a vital part of the global economy. 

This means that the group is likely to continue to churn out returns for investors no matter what the future holds for the UK economy.

Over the next few years, Shell’s earnings should climb steadily higher as the company continues its integration of recently acquired BG Group and cuts costs further to deal with the slump in oil prices. Asset sales should bolster the enlarged group’s balance sheet while improving margins as low-return assets are sold off.

Shares in Shell currently trade at a forward P/E of 23.7 and support a dividend yield of 7.2%. Management has announced its commitment to the dividend for the foreseeable future so a payout should be secure no matter what the outcome on 23 June.

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Lady wearing a head scarf looks over pages on company financials
Investing Articles

Is April a good time to start buying shares?

Wondering whether now's a good time to start buying shares to build wealth? History suggests it is, says Edward Sheldon.

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How much passive income could a Stocks and Shares ISA pump out every year?

Regular investing inside a Stocks and Shares ISA could lead to the equivalent of £141 a week in tax-free passive…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With the FTSE 100 down 5%+ investors should remember this legendary quote from Warren Buffett

Warren Buffett is widely regarded as the greatest investor of all time. And he says that the best time to…

Read more »

Inflation in newspapers
Investing Articles

1 FTSE 100 stock that could benefit from higher inflation

For most companies, inflation is a risk. But for one FTSE 100 firm, higher input costs could be an opportunity…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

The 2026 stock market sell-off could be a rare opportunity to build wealth in an ISA

The recent stock market sell-off has led to some shares falling 20% or more. This could be a great opportunity…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

It’s down another 13%! Analysts were dead wrong about the Greggs share price

The Greggs share price continues to fall and analysts have been revising their share price targets down further. Dr James…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Is the stock market about to reach breaking point?

Private credit has a problem with the emergence of artificial intelligence. And it could be set to create issues across…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

A once-in-a-decade chance to buy this S&P 500 stock?

As investors focus on oil prices and the conflict in Iran, Stephen Wright's looking at potential opportunities in the S&P…

Read more »